Abstract | BACKGROUND: METHODS: RESULTS: The safety of the FEC-HD regimen was described previously. Among 102 patients who underwent surgery, a pathologic complete response (pCR) was achieved by 23.5% of patients with breast tumors and by 31.4% of patients with involved axillary lymph nodes. The overall pCR rate was 14.7%. One hundred nine patients received FEC 75. After a median 10 years of follow-up, the disease-free survival (DFS) and overall survival (OS) rates were 35.7% and 41.2%, respectively. The median DFS was 39 months (95% confidence interval [95% CI], 25-53 months), and the median survival was 61 months (95% CI, 43-79 months). Five patients developed a temporary decrease in left ventricular ejection fraction without congestive heart failure. In the lenograstim group, 1 patient developed acute myeloblastic leukemia M2, and 1 patient developed myelodysplastic syndrome. CONCLUSIONS: FEC-HD induction chemotherapy followed by FEC 75 maintenance regimen had moderate and acute long-term toxicities and lead to high DFS and OS rates in patients with IBC.
|
Authors | Corinne Veyret, Christelle Levy, Philippe Chollet, Yacine Merrouche, Henri Roche, Pierre Kerbrat, Pierre Fumoleau, Pierre Fargeot, Pierre Clavere, Bernard Chevallier |
Journal | Cancer
(Cancer)
Vol. 107
Issue 11
Pg. 2535-44
(Dec 01 2006)
ISSN: 0008-543X [Print] United States |
PMID | 17054108
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Copyright | (c) 2006 American Cancer Society. |
Chemical References |
- Placebos
- Recombinant Proteins
- Granulocyte Colony-Stimulating Factor
- Epirubicin
- Lenograstim
- Cyclophosphamide
- Fluorouracil
|
Topics |
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, adverse effects, therapeutic use)
- Breast Neoplasms
(drug therapy, pathology, radiotherapy, surgery)
- Chemotherapy, Adjuvant
- Cyclophosphamide
(administration & dosage, adverse effects)
- Disease-Free Survival
- Dose-Response Relationship, Drug
- Epirubicin
(administration & dosage, adverse effects)
- Female
- Fluorouracil
(administration & dosage, adverse effects)
- Granulocyte Colony-Stimulating Factor
(administration & dosage, adverse effects)
- Humans
- Inflammation
- Lenograstim
- Placebos
- Recombinant Proteins
(administration & dosage, adverse effects)
- Remission Induction
- Survival Rate
|